Premium
Bone marrow transplantation for chronic granulocytic leukemia
Author(s) -
Bacigalupo Andrea,
Frassoni Francesco,
van Lint Maria Teresa,
Occhini Domenico,
Pittaluga Pier Antonio,
Repetto Mario,
Piaggio Giovanna,
Sessarego M.,
Caimo Attilio,
Congiu Angela,
Marmont Alberto
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19861115)58:10<2307::aid-cncr2820581025>3.0.co;2-h
Subject(s) - medicine , chronic granulocytic leukemia , discontinuation , surgery , leukemia , total body irradiation , bone marrow , transplantation , immunosuppression , chronic leukemia , gastroenterology , acute leukemia , chemotherapy , cyclophosphamide
Thirty patients with chronic granulocytic leukemia (CGL), were given cyclophosphamde 60 mg/kg on each of 2 consecutive days, followed by total body irradiation (TBI) 10 Gy and an HLA‐identical bone marrow transplant (BMT). Eleven patients were in the accelerated phase of their disease (CGLacc) or in second/secondary chronic phase (CGL‐2CP), with a median age of 33 years: four patients died of transplant related complications, and four of recurrent leukemia; three patients are alive and well 19, 31, 33 months from BMT. The actuarial 33‐month survival is 27%. The actuarial relapse rate is 50%. Nineteen patients were in their first chronic phase (1CP), with a median age of 32 years: three died of graft versus host disease (GvHD), two of infection, and two of acute respiratory distress syndrome (ARDS); 12 are alive and well 6 to 29 months post‐BMT. The actuarial 29‐month survival is 63%. The actuarial survival of patients younger than 30 years is 63%, compared to 62% for patients older than 30 ( P = 0.1). The survival of patients grafted within or after 24 months from the onset of CGL is respectively 87% and 45% ( P = 0.04). None of the patients grafted in 1CP had a true hematologic‐cytogenetic relapse. The Ph′ chromosome was detected on one occasion in two patients 12, 13 months post‐BMT: they both remain hematologically normal and Ph 1 ‐negative 3 to 6 months later, after discontinuation of cyclosporin A. This study confirms that survival exceeding 60% can be obtained in CGL in the first chronic phase, whereas less than 30% of patients will survive if grafted in accelerated, second/secondary chronic phase, mainly because of leukemic relapse. The duration of the disease seems to be relevant to the outcome of the transplant. The effect of post‐transplant immunosuppression, in our case cyclosporin A, on the interaction between normal and Ph 1 ‐positive hemopoietic cells, may deserve further attention.